[e-farmacos] WHO Pharmaceuticals Newsletter No. 3, 2007

["Canas, Martin" <macanas@netverk.com.ar>]

WHO Pharmaceuticals Newsletter No. 3, 2007 WHO Pharmaceuticals Newsletter 
No. 3, 2007

Regulatory Matters
Antidepressant medications -- Black box warning update about increased risks 
of suicidality ... 1
Desmopressin nasal spray -- Primary nocturnal enuresis (PNE) no longer an 
approved indication ... 1
Gadolinium-based contrast agents -- Boxed warning about risk of nephrogenic 
systemic fibrosis ... 1
Nelfinavir (Viracept) -- Marketing authorization suspended due to possible 
contamination with genotoxic substance ... 2
Nimesulide-containing products for oral use -- Marketing suspended in 
Ireland due to reports of liver failure ... 2
Tizanidine -- Concomitant use with fluvoxamine or ciprofloxacin 
contraindicated ... 3
Trimethobenzamide -- Suppository drug products not approved ... 3

Safety of Medicines
Bevacizumab -- Tracheo-esophageal fistulas if given with concurrent 
chemotherapy and radiation in SCLC patients ... 4
Citrus auranthium (bitter orange) -- Reports of adverse cardiovascular effects ... 4
Clozapine -- Reports of myocarditis ... 4
Metformin -- Risk factors for lactic acidosis ... 4
Oseltamivir -- Update on behavioural effects ... 5
Pioglitazone -- Long-term treatment associated with increased incidence of 
fractures in women ... 5
Quetiapine -- Pancreatitis and thrombocytopenia ... 5
Rituximab -- Three cases of progressive multifocal leukoencephalopathy ... 6
Rosiglitazone -- Issues of cardiac safety ... 6
Vinca alkaloids -- Should only be given intravenously ... 7

Feature
Building pharmacovigilance capacity: a multi-method approach ... 8

Proxiammenmte disponible en:
http://www.who.int/medicines/publications/newsletter/en/index.html

Saludos,

Martin

Martin Canas
GAPURMED
La Plata 
(Argentina)
macanas@netverk.com.ar